KURA - Earnings call transcript Q2 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the 2018 Kura Oncology second quarter financial results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct question-and-answer session and instructions for how to participate will follow that time. [Operator Instructions].

As a reminder, this conference call is being recorded. to host like Mr. today's now would introduce for your conference, I De Investor of Vice Pete President Relations. Spain, you Sir, may begin.

Pete De Spain

Thank you, second Oncology's to welcome operator. Good quarter afternoon conference and Kura call.

Wilson, call Dr. and Gualberto, our and are on Executive Development Antonio from of Medical me and Chief the Dr. Joining Troy Chief our Head President Officer; Kura Officer.

management's concerning turn filings Kura With like forward-looking that represent you will over materially include as from Please or and Oncology to statements to now Such the on I to Kura's on judgment which today's uncertainties over expectations. cause information could CEO actual President Dr. to and of risks call SEC, I Kura results today will remind Before call Wilson, the factors to the would affect with current based risk results. that, may turn that differ company. I SEC of and Dr. expected could available are call the the from Wilson, statements refer involve for Oncology. Troy the website that

Troy Wilson

financial for wish as prepare our also and to leadership additions as registration-directed he John we personnel, three Henson finance, his which included included core commanding where behalf welcome want team, all since to Marc Pete, and after his officer. had spent of the earned position years and in on members operations John lead her at the all them leadership, take in the chief an Air in dedication space, joining banker team August operations, Celgene all thank years officer Receptos Doctorate transactions, the in Marc biology corporate leadership our development. chief chief operations healthcare of raising entire you assurance, operating investment in John Coast history and inception. focused management leadership appreciation valuable last Stifel pharmaceutical of Johns the and as significant a like into recently hard Marine On Marc CFO the from banking to seamlessly and working the and Officer. will best. is for for team functions joined to sincere we opportunity and clinical by as Kura's the with the board where her I start help ensure Medicine Previously, of to officer deep and an strength Station and strategic together. strategic us University first Heidi career you, oversaw responsibilities Thank Hopkins I'd Marc on degree Kura. to undergraduate capital he our He Marc person services Farnam biopharma. and finance, distinguished for advisory want most head us he express of Kura's in this and and of the Medicine work newly I thank officer personnel. newest business at this created for leading X,XXX of companies, of installation Kura trial molecular Princeton XX. and Miramar where us of With a program Grasso He'll role to quality professional facilities John's us both as Dr. comes West of step to from knowledge in my biotechnology are start to this company's operations, ideal as exposure expanded services month our and Farnam. afternoon. University. leadership introducing its past XX Corps, School are to at that

drug lead of me our brief multiple with a candidate, tipifarnib. tipifarnib solid Now, tumor evaluating you each hematologic on update and programs currently indications. give We're let our development in beginning

HNSCC. carcinomas, HNSCC of advanced cell had Our primary we HRAS efficacy neck endpoint RUN-HN. achieved to Last its and our trial We mutant is indication prior head ongoing squamous mutant, in most announced enrollment. call fall, completion tipifarnib HRAS II this that of or in Phase trial

As of confirmed with of intent-to-treat update we patients data our of five six in responses response reported median six months. nine on than or five an duration more February, evaluable patients of last basis, in of a

in XX% Munich at reminder, the next the XX%. a the squamous for in HRAS second cell to XXXX in in other European Society plan three the from October. of response Medical As our are of We exploratory update this an approved to line Congress rates in present cohort, Oncology including mutant carcinomas patients for agents range presentation trial, oral

call, provides As oncology-focused to our make continue next-generation support HNSCC including our patients the agreement a oncogenic with for physicians in technology We've to identify treatment internationally last based HRAS Belgium, sequencing may on with significant HRAS whom signed we OncoDNA discussed option. screen to tipifarnib healthcare and an mutations patients population. OncoDNA, ability an we company for patient enrollment. overall strides mutations, with be in with potential among

enrollment with OncoDNA, progressing also on With we recently patients first who setting in our our patient HNSCC manner, identifying identifying mutant of we treatment with in HRAS later frontline this HRAS and tracking patient patients the newly-diagnosed the RUN-HN those in for enrolled enrolled study. a frontline treatment. are mutant help HNSCC in potential Indeed, after

additional sites study We now approximately for with open worldwide, open XX enrollment. locations clinical to continue

we designed which factors should years primary initiated trial last pattern we the This histology or squamous to of with of global, upon history order those Spanish study, date this To metastatic trial type, patients and designed mutant with lung clinical HRAS potential non-interventional has cohort, our later line as as cohort. to investigator-sponsored registration-directed multicenter to age, a assumptions, for type patients for trial. using a considered that LSCC, results similar of a these interest. treatment at and with XXX mutations, provide trial SEQ-HN to well of cell rate. genetic with SEQ-HN trial study Cancer AIM-HN. We're as Group, This these responses is initiate support therapy, is cohorts is AIM-HN wild enrollment as to two the recognize a and such is XX a preparing of point approximately mutant we're the patients take need potential as HNSCC of rate activities to a and Spain Meanwhile, the HRAS platinum-based tipifarnib efficacy second-line treatment. approximately designed patients natural case-control mutations in HNSCC. cooperative two in XXX us call, as evaluate of a difference initiated confirmed endpoint and LSCC than with response reject of concept study collaborating therapy, Lung for received enrollment. should fully with and XX of This hypothesis HRAS in been this observed year. commitments the ORR, the least of enrolling private identify therapy. from group a opportunity SEQ-HN, treat considerations. of better the registration-directed AIM-HN, while patients a potential Based null are well now helping and result HRAS between proof power mutant and more for and NDA tipifarnib us and this overall in the with public endpoint. – who who commercial close the a mutant a carcinoma the to recurrent XX% are XX%, could as into has HRAS estimate tipifarnib enroll. in understanding post-approval matching consists outcomes trial on to screening of prior few is The The HNSCC. meet As to approximately with HRAS at its Based month also against or recurrent feedback the as in for primary targeting also have per FDA, expect AIM-HN centers is as metastatic startup disease encouraging we're now Since HRAS sites open of HNSCC now we've RUN-HN patients detect and on opportunity, ORR oncology two the RUN-HN. has XX% worldwide in efforts, of hypothesis positive statistical null in

and We clinical continue the the very generated tipifarnib as preclinical encouraged we've mutations. tumors data of to for treatment characterized by solid by potential supporting be a HRAS

in Our data use to is HRAS mutant an for to a to other we possible, soon unmet its potential need. approval work marketing as while high HNSCC of diseases to as support goal include broaden application package generate

tipifarnib that our patients malignancies in Now, our can a for in attention MDS tipifarnib. activity Previously hematologic represent clinical AML, opportunity turn studies also with malignancies, and conducted demonstrated let's which development strategy PTCL. drive hematologic including certain to significant

hematologic is AITL first as ongoing begin was in or been of CXCL-XX of patients prospectively with no Based of its molecular XXXX, CXCL-XX a we on potential two activation who MDS region actively cells in and in cohorts. to prime and single PTCL those Phase AML. in including activity target certain the of three and the T-cell CMML However, myeloid that to malignancies, potential biomarkers of we've of presented with therapeutic neoplasias, trials. marrow a the the action lymphoma identified into the untranslated findings mechanism PTCL of populations. to as and activity and variation The pathway our explain observations, identified absence pathway biomarkers enrolling II X' the of could Patients angioimmunoblastic CXCL-XX PTCL, was and patient myeloid continue bone have validate In tipifarnib nucleotide gene. that validate homing new December tipifarnib's working trial these to three

CXCL-XX other forward the from hematologic of will end to indications continue PTCL to this and year. providing pathway encouraged biomarker-enriched we tipifarnib to for be potentially promise who and respond the look by We patients holds initial that identifying data

ERK quickly kinase have tumors or activity pathway. attention pipeline our mutations with let's as to two turn with emerging patients beginning the for inhibitor, treatment due our a programs, We're KO-XXX. in mechanisms advancing to that potential dysregulated other KO-XXX Now, MAP

is escalation schedule tumors KO-XXX ERK dose patients, dose will in in solid that to tumors I KO-XXX evaluate genetically-selected define inhibition. to sensitive We're whose ongoing. working are Phase enable and a trial Our to of us

with potential expect and demonstrated clinical advancing clinical leukemia, expecting small of for selective genetically-defined Given has oncogenic completion molecule successful acute we in late activity data present that in early those in escalation of NPMX- that submit application currently we're the studies, a trial, next I IND-enabling menin-MLL We're dose now to to and year. subsets KO-XXX, mutations the IND potent still we're inhibitor an of XXXX. also or driver KO-XXX in Pending XXXX interaction Phase including antitumor phase the of DNMTXA.

loss administrative of the quarter second quarter increase compensation, to XXXX. $X.X call second increase XXXX per expenses the $X.X expenses quarter due $X.X per to more R&D on expenses Next, loss invite review the The $XX.X tipifarnib. or Research provide of the quarter here G&A million the of today were quarter for patent-related million and to XXXX. XXXX compared I'll share-based development quick financial overview the and clinical for for compared activities to net of primarily XXXX and our in filed or fees detailed quarter increases second a $X.XX quarter and of million share XX-Q in costs. increase in second second a $XX.X you $X.XX the were XXXX. a was due related for to non-cash second to discussion. The for million was million expenses an was primarily to results $XX.X professional Net our of of for for million General compared the in development share for

XXXX, of short-term XXXX. XXXX had million July cash As with public stock. June on XX, equivalents we compared a of cash, of as Subsequently, December common offering X, $XXX.X completed and of million we $XX.X investments XX,

XX, adjusted As equivalents a net had at in $XX.X from in Kura cash the public and proceeds the June XXXX. pro million for on investments cash, million forma offering, resulting $XXX.X basis

July our We terminated ATM facility in also XX.

who the I'd participated resources mutant our leadership balance be our second will offering HNSCC. in in HRAS million, progress vote confidence. approximately cash, we've and including operations We everyone our the half thank to pipeline of the We I'm registration upcoming with a our equivalents investments our of of strengthened year your opportunities on to the past $XXX potential positioned data our made with execution. to team, We've through like current us that current our very advance the milestones, operational our from identify a focus HRAS series mutations, directed sheet. ability pleased with additional create improved giving of patients and to for screen began fund trial over expect to quarter sufficient with upcoming tipifarnib and pipeline enhanced cash through short-term XXXX. recent

for look forward updates will we value in and you, grateful are significant toward our support ahead. your attention work for your appreciate patients afternoon and I for We shareholders. and to continue months to the providing additional this creating

Before we milestones. into the quickly Q&A me jump layout let anticipated our section,

initiation our end of this of by year. For tipifarnib, the registration-directed trial

Additional ongoing from our trial mutant carcinomas exploratory other data cohort our RUN-HN in at an cell and HRAS presentation squamous oral of ESMO.

cell the dosed biomarker-enriched the potentially this end of data malignancies carcinoma and in patient other and squamous investigator-sponsored in First study mutant by HRAS lung year. hematologic PTCL

we're late operator, XXXX trial now for KO-XXX, for in early XXXX; submission dose questions. an and With in IND ready XXXX. of For data I that, application or our KO-XXX, from escalation Phase

Operator

Instructions]. Understood. [Operator

comes Beatty with from Citigroup. Our first Joel question

is line now Your open.

Unidentified Analyst

calling you for is my and Thank This guys. Joel. call Hi, for Sean questions. in taking my [ph]

how at package of will scope previous data be large we data expect see ESMO, can So, data similar to a and that readouts? package to in

Troy Wilson

thanks HRAS other mutant patients. can open What expect. can't we We the enrolling can and the carcinomas the in into the in Sean, get specific is number are you HNSCC that question. both additional patients cohort and of you tell cohort squamous cell for

run sort the with is as whatever point of given parameters enrolling ESMO, update the specifics we've the HRAS approximately of a HNSCC front on presentation or the don't And But what past. of that study, full The currently are we the said to give cohort in month. as we’ll either give patients rate other abstract per that is we'll want currently to numbers on at that patients two expect. or on thing an patients we've mutant more at

Unidentified Analyst

additional brief the exploratory but you Sure. follow-up, you if Thank study? have can you. color, what in you've not sure for That any other just indications the disclosed sense. makes And I'm provide enrolled

Troy Wilson

No.

a of the that are haven't enrolled carcinomas. we're which being in squamous the We to additional forward other in provide the position cohort presentation ESMO, cell specifics disclosed third that additional looking at oral be patients to. of information at We'll

Unidentified Analyst

sense Troy. a Thank the frame of Great. And indications can give lastly, in your for programs? then, you HemOnc you, your us in how those success analyses threshold retrospective

Troy Wilson

to you're I'm make sorry, Can I Sean. understand I what you sure again? ask question want asking. that

Unidentified Analyst

readouts frame of gauge I'm your analyses trying success in how of the just end retrospective absolutely. Yeah, in to your thresholds for the HemOnc XXXX. upcoming the indications

Troy Wilson

Sure.

may, can I understand Okay, me it. let question If I that you. answer Sean, ask he Antonio for if

Antonio Gualberto

is the that What importance of say or data reproduce I this similar markers indications. across several will to the ability is –equal similar

we tipifarnib. take patients fact responders identify benefits CXCL-XX at the can and that that we can receiving we are using reproduce data that now able are retrospectively and lymphoma data select AML can also see in from we in that So, potentially that clinical that indications CMML patients ongoing patients, to our look and

because important the are on right track. telling quite us that's think I it's we So, that

There's they now definition patients independent could path in these years number do oncogene studied population. of outside be in that is subset, this past track and not many the of of was we the know a the have subsets but that ago. we identified the very indications the that with now patients well, [pj] breeding you right HRAS, So, the for responses, that are

Unidentified Analyst

Troy. Appreciate and Antonio you, Thank it.

Troy Wilson

Thanks, Sean.

Operator

Wainwright. Thank next question from with Joe you. comes Pantginis And our H.C.

open. is now line Your

Joseph Pantginis

Hi, guys. question. the Good afternoon. Thank you taking for

HNSCC First, with to quick regard just relatively a question the program.

sites. your expanded You've

You're patients month, per which enrolling about great. is two

patients as say. or of potential you growing the from to identification, patients or two-year be could said take that patients RUN-HN SEQ-HN, conservative? for this enrollment to as on curious, anticipate database two Just expect approximately with you years enroll, that the AIM-HN, about well I from Do XX you a the should the have based is regard you timeframe there

Troy Wilson

for yes, to potential for that thanks was the question put it's preference With as the report to the It's estimates initiation to is for conservative may timeline your it and can And respect two-year of thanks projecting Joe, we question, at our appropriate. also enrollment you then, be read. we're conservative. out, fun this AIM-HN the our that there adjust that point. be

just be through approximately go for we're we open though was there sites – of bringing currently we're that point clinical you patients go prefer because as shorter potential there expecting well of through enrollment both as time. online. continuing where the the we that to endpoint XX happened pleased – its And are give the than the But bodes It's of sites XX in and the completion take trial. correctly Even month. with bringing you're I out and a think prior sigmoidal in rate we're on II, for projecting online, and that's be for sites at that trial RUN-HN. approximately enrollment meet two there to of curve full indicated still guidance stand to is open, You the so for timeline conservative, enrollment, currently we're current sort going Phase to as two to think to that primary enrolling XX years sites with per efficacy is conduct approximately we're we a what enrollment of we're the the pivotal sites today we've past, the going the that to period

Joseph Pantginis

Thank No, obviously, me. question, indications a switch And tipifarnib, PTCL that's you. others year. for hem this curious, if just potentially so and just be later forward I'm I data really bear quickly to multipronged to the with for looking might could helpful. this we're

studies? on list test wish any might ramp third, be on then readiness now might of studies quickly to, that might what data. combos balance mechanism a that additional Thanks. have like. are you potential the these for look curious, strong upcoming how regard biomarker dependent potential based up action Obviously, With Just sheet, the and And the CXCL-XX? be one, considering to able you you very of

Troy Wilson

Thanks Sure. the question. for

currently at of in that Lung That as of you enrollment that HRAS the we're And encouraged mutant inhibitors of well. to therapeutic trial So, and the this the tumors. the squamous year. tumors, Group. independent the data balance people of that just draw the cell notice and the around carcinoma attention pathway looking other Phase be the a that of with context providing the update data addition and have most have farnesyl looking where thus notion in really kind Antonio hem forward of data, we ongoing update other we're them. And evaluate hope in a data to diseases, the continuing but shown significance malignancies potentially to that class for HRAS. your no that data-driven the indications where, represents RUN-HN, ever tipifarnib HRAS respect appreciate we're to The solid the the the way we've enriching got of we update starting has to other mentioned transferase is Spanish as certainly is in mutant CXCL-XX AIM-HN, target toward initiation With well Janssen to agents in ones given and of patients, we the and with a an as with as that's both independent to the strength of to Cancer mechanism did anecdotal we're patient ASH, that that malignancies we then CXCL-XX to of study. strength that represents the lung pointing immediate strong very reports the reinforce his continuing the to enrichment the you've year, assigned forward hematologic of indicated, II solid most to Antonio in sheet, means both gives in Sean's support. we molecular opportunity the – end of think is, far of that the was activity, response really will at open an as likely providing that question, action later providing implications With If us but respect

of can for additional sort we how be evaluate for to our to pipeline opportunities. And in where like we create can we'd a prioritize more places continue continue spend resources patients. value to we we think where look I position to forward

Joseph Pantginis

it. Great. I'm Thanks lot, Go Yeah, a appreciate I sorry. ahead. Troy.

Troy Wilson

that So, combinations, you is preclinically. about asked also on going

trials data combination preclinical on with of So, continue to more potentially there's in studies a conduct number to studies. but no currently months tipifarnib, the we clinical come on And those ahead.

Joseph Pantginis

Thanks Great. again.

Troy Wilson

Sure.

Operator

from comes question JMP next Konstantinos the And Securities. you. with Aprilakis Thank

Your open. line is now

Konstantinos Aprilakis

tipi Thanks readout very a for versus my Hey, I the your and assuming on alter clinical this establish in the get expect checkpoint plus if Does significant impact what first-line advantage HNSCC, and questions. you inhibitors plans data suggesting for your was on to pembro for could platinum. thoughts any guys. frontline. development I way taking these wondering themselves in any, recent much if survival have cetuximab practice,

Troy Wilson

the for you thank question. Konstantine, Sure.

Antonio Let your me question. answer let

Antonio Gualberto

Hi, Konstantine.

So, colleagues. obviously, patients certainly, to way, our positive us. data congratulate combination therapies is that will may we And everybody. seem for be easier for it In good beneficial a

data the obviously, saw, You markers. the about

platinum So, that care immune our identification can population, thing that in standard the second targeted that based Also, – is to cement account combined only the of to does with those were other the by line. recurring therapy And only the therapies. the actually initial the it susceptible have into it of therapy. therapies you on require take favor may a frontline followed immune fact be position

that and HRAS number one to have a a expansion drivers of there's of many position both the potential in franchise benefits the patients So, as fact in of how also the tipifarnib tested main possible. we of is

other any targeted to be receive. will – patient tested are may the that So, will possible you test if departments the imagine compounds, but pathology for for patients that only IO therapy going for

the as only other for such So, targeted that opportunities therapies increased tipifarnib.

Konstantinos Aprilakis

you. Got it. Thank

setting? there. reason Anything cetuximab sort tipi a a a therapy, can in so inhibitor to and in plays of to post play resistance believe driving So, to say there's you that checkpoint post role in has HRAS part certainly setting, a

Antonio Gualberto

data I with shown and you head resistant what the we mutation, patients inhibitors. And they're that response. that – checkpoint to experience to not you remember fairly not these have HRAS neck can but patients recurring seen but tell did anecdotal, only cetuximab, Well, also a that is have

in once And be But ideal will But sorry, progress therapy patient has with we are in physicians do. future, And initial is tipifarnib. post the the setting. that an the from So, setting. they step, the the therapy, – patient yes, IO post once mutation. the determine to carry the the have in candidates obviously, to some will patients there's work that for what HRAS

We the will what the in have our show line firs responses to initially is post depth, this initially duration of setting.

Konstantinos Aprilakis

Antonio. Okay, Thank you, fantastic.

Antonio Gualberto

Sure.

Operator

Thank question Shibutani Chris you. And with our from next comes Cowen.

Your line is open. now

Chris Shibutani

that's Thanks done very color little you us much. Spanish if Perhaps cooperative bit a the study just provide group. the more on lung with could with being

the data sense give that? you number initial for enroll which mentioned and consider some has we patients a been then upon you're us expecting the Can the You might on that group maybe initiated. to perhaps getting some of study timeline perhaps

Troy Wilson

Sure.

is studies the to we've in very in design proof the So, concept study used other Chris, that of similar the past.

approximately looking patients certain you're So, interest. of for a response and rate XX

difficult. is, at a study. control. terms under group of cooperative that's more obviously, timeline, In It's all Kura's not This

diagnostic a is between lung number need And you X% thought the of X% we we the at squamous it's might with lung Spanish be. give patients. the that with But cancer to providing to that. mutation enrollment to think in support screening able do this lung of We're group the expect sites of supporting premature frequency probably positioned One I actively cancer, went reasons estimated on to some group of guidance and Spanish the of what that cancer testing. well we be terms was

they're are of these efficient ISTs, know of enrollment that on the updates. with don't cost-efficient more group. this proof-of-concept any you much cooperative I to in way way near-term give or data, the generating but expectations able or studies control be in very And As kind a largely we'll

Chris Shibutani

the data forward that we're then, Got we'll that. coming it. up And to look ESMO, at with

I think what to I as in durability? response us well provide you about Can for You as you. you context presentation on being think earlier you ESMO? follow-up quarter, did with well. help meeting then, that, reasonable Is having and of no would a there possibility when that And table some in focus with be the rate. terms a to a think the of spoke the longer triple Thank in the was at

Troy Wilson

take Chris. let's So, question first, your second

to either at intent data that Our we presented would the ESMO meeting. triple was like or the see

give February, folks an so the ESMO. that very last got we've excited. in data update, was with the We're oral Just since to update we're excited an at fact also presentation

speaks durability, So, With therapy. I our therapies the duration that think a patient of that otherwise respect what excitement around approximately sea is months immune in of the targeted median see agency it's to to to want a population. expectation six the across would

a seems reasonable need unmet the low high of the months and given sort the So, and rate relatively line is it proxy. agents, like among six response short PFS approved second

terms what in of shooting for we're that's durability. So,

Chris Shibutani

final to your kind of consensus a runway realize it's it. cash when I and I a range presently board of the look Got at comment CFO out having month, And bringing And balance estimates, four then, instance, of you with you burn but get XXXX on end your to you're at about the denominator the into I a XXXX analysts. XXXX, question. sources, or out million. me XXXX? from can help over you according operating comes think But with five that would expense maybe the consensus in what $XXX to see, and understand for my

great. that If would bit you comfortable could with little be to Thank is more a So, during get that, where help you. period? consensus should spending to be tempered XXXX, view or Street are out you the that us with us to

Troy Wilson

us $XXX pivotal to Chris, the anticipating just that needed. of I we're of said the anticipated prepared enrollment remarks, data clarify, as anticipated durability So, months includes and trial the XXXX. the will through That in six million take the

guidance pivotal opportunities guidance the should I last. this our is, feel XXXX we give a through we number and on expect confident What other through we for give of been have don't hope we've us cash far quarterly And trial runway point, do And and the pipeline. consistent, forward and we to so, on at the we take requirements spend. conservative with give is us which that the how

the So, clarifies hopefully, for that you. situation

Chris Shibutani

members. Great. forward to look Appreciate meeting it, Troy, Thanks. team your and

Troy Wilson

Thanks.

Operator

Thank Instructions]. you. [Operator

question comes Partners. next Our from with Jonathan Chang Leerink

Your line is now open.

John Barrett

How diagnostic John my a This you strategy mutant on about is Jonathan Chang. for for cancers? taking HRAS Hi. companion thinking for tipifarnib Barrett in are questions. Thanks

Troy Wilson

Sure.

your we question. – sort to of So, several answers

trial said, and to were We allows of very are to test agency those in mutant patients. as activities diagnostic. – pivotal regulatory identify was of the the any accompany approved the HRAS And that agency ongoing shape The existing a that the PCR-based we It's that patients. developing to doesn't a use are That us the being pleasantly the to trial. part surprised actually will initiation use companion framework. for NDA require companion diagnostic us test enroll pivotal good

sequencing there new US, success the care. as Ex-US, That's world. of next the Europe, in So, highlighted gen the NGS looking are of a well standard rest is in very relationship FoundationOne we why toward had of as good number OncoDNA. we've with now platform approaches. the That's current an the with

therapy. being as identified to the of So, long good next-generation using patients likely we that's by AIM-HN as And sequencing. are the screened targeted our would whatever expect that on patients method, trial for be standpoint, a majority will

We will, satisfied in that however, diagnostic. And is effort be ultimate of prepared terms the have ongoing. requirements to companion regulatory the

John Barrett

Great, thank you.

Operator

to further this Troy back no questions call CEO, closing Wilson, to like over showing remarks. for turn the I'm at And I'd time. any you. Thank

Troy Wilson

for Great. our And thank all call you in today. participating questions. again you for the once Well, thank

contact or if And the at seeing have myself. feel free conference everyone. have questions, Next in forward meantime, in evening, And additional you We look to good please Wedbush New week, we'll many again. a any you to Thank you Pete of there. York. be the

Operator

Ladies conference. and and all your today's you thank may for great in participating gentlemen, concludes day. Everyone, disconnect. you This program a have

Kura Oncology (KURA) 6 Aug 182018 Q2 Earnings call transcript